

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

210997Orig1s000

210997Orig2s000

Trade Name: GLYRX-PF for intravenous or intramuscular use
Generic or Proper Name: (glycopyrrolate injection)

Sponsor: Exela Pharma Sciences, LLC.

Approval Date: July 11, 2018

Indication: NDA 210997 provides for the use of GLYRX-PF for the following indications which, for administrative purposes, we have previously designated as follows:

NDA 210997/Original 1 – For use in pre-anesthesia, intraoperative use, reversal of neuromuscular blockage

NDA 210997/Original 2 – For adjunctive use in peptic ulcers.

CENTER FOR DRUG EVALUATION AND RESEARCH

210997Orig1s000

210997Orig2s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Summary Review	X
Officer/Employee List	X
Office Director Memo	
Cross Discipline Team Leader Review	
Clinical Review(s)	X
Product Quality Review(s)	X
Non-Clinical Review(s)	X
Statistical Review(s)	
Clinical Microbiology / Virology Review(s)	
Clinical Pharmacology Review(s)	X
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

210997Orig1s000

210997Orig2s000

APPROVAL LETTER



NDA 210997/Original 1
NDA 210997/Original 2

NDA APPROVAL

Exela Pharma Sciences, LLC
1245 Blowing Rock Blvd
P.O. Box 818
Lenoir, NC 28645

Attention: Aruna Koganti, PhD, MBA
Executive Director, Clinical Programs and Regulatory Affairs

Dear Dr. Koganti:

Please refer to your New Drug Application (NDA) dated September 5, 2017, received September 12, 2017, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for GLYRX-PF (glycopyrrolate injection), for intravenous or intramuscular use, 0.2mg/mL.

NDA 210997 provides for the use of GLYRX-PF for the following indications which, for administrative purposes, we have previously designated as follows:

- NDA 210997/Original 1 – For use in pre-anesthesia, intraoperative use, reversal of neuromuscular blockage
- NDA 210997/Original 2 – For adjunctive use in peptic ulcers

We have completed our review of this application, as amended. NDA 210997/Original 1 and NDA 210997/Original 2 are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text, submitted on July 6, 2018.

WAIVER OF HIGHLIGHTS SECTION

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content

of labeling must be identical to the enclosed labeling (text for the prescribing information). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE-CONTAINER LABELS

Submit final printed carton and container labels that are identical to the enclosed carton and immediate container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3)*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 210997.**” Approval of this submission by FDA is not required before the labeling is used.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the prescribing information to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft

Guidance for Industry (available at:
<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the prescribing information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>.

For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see

<http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

EXPIRATION DATING

GLYRX-PF is granted an expiry of 24 months when stored at 20° to 25°C (68° to 77°F), with excursions permitted between 15° to 30°C (59 to 86°F).

COMPARABILITY PROTOCOL

The comparability protocol is acceptable with the required additional stability and extractable / leachables data to be submitted in a prior approval supplement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Eva Yuan, Regulatory Project Manager, at (240) 402-2476.

Sincerely,

{See appended electronic signature page}

Rigoberto Roca, MD
Deputy Director
Division of Anesthesia, Analgesia,
and Addiction Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosures:

Content of Labeling
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

RIGOBERTO A ROCA
07/11/2018

7